Clinical Pharmacokinetic Assessment of Lazertinib in Healthy Adult Participants: Effects of GSTM1 Genotype [0.03%]
健康成人受试者中Lazertinib的临床药代动力学评价：GSTM1基因型的影响
Jaydeep Mehta,Chuck Thompson,Ellen Scheers et al.
Jaydeep Mehta et al.
Background and objective: Lazertinib, a potent and irreversible third-generation oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has shown promising efficacy and favorable tolerability in EGF...
Susan J Keam
Susan J Keam
Published Erratum
Clinical drug investigation. 2025 Oct 9. DOI:10.1007/s40261-025-01491-2 2025
Efbemalenograstim Alfa, an Fc Fusion Protein, Long‑Acting Granulocyte Colony-Stimulating Factor for Reducing the Risk of Chemotherapy-Induced Neutropenia: Results of a Phase II Randomized, Multicenter, Open‑Label Trial [0.03%]
长效粒细胞集落刺激因子EFBEMALENOGRASTIM ALFA（FC融合蛋白）降低化疗诱发的中性粒细胞减少风险的II期随机、多中心、开放标签试验结果
Dongmei Ji,Shufang Wang,Wei Yao et al.
Dongmei Ji et al.
Background and objectives: Neutropenia is the most severe hematologic toxicity of myelosuppressive chemotherapy. The objective of this study was to evaluate the safety and efficacy of efbemalenograstim alfa versus filgras...
Budget Impact and Financial Analysis of Outpatient Dalbavancin in an Urban, Non-Teaching, Community Hospital [0.03%]
达巴万辛在城市非教学社区医院门诊的应用对预算影响及财务分析
Karan Raja,Brandon Chen,Onrina Chandra et al.
Karan Raja et al.
Background: Acute bacterial skin and skin structure infections (ABSSSI), diabetic foot infections (DFI), and osteomyelitis often require extended antimicrobial therapy courses. Dalbavancin's long half-life allows outpatie...
Disproportionality Analysis of Pulmonary Adverse Events Associated with Trastuzumab Deruxtecan Using the Japanese Adverse Drug Event Report Database [0.03%]
基于日本药品不良反应事件报告数据库的T-DXd肺部相关不良事件信号 disproportionality 分析
Yuko Kanbayashi,Risa Morioka,Keiko Hosohata
Yuko Kanbayashi
Aim: This study was conducted to examine disproportionality, times to onset, incidence rates, and outcomes of trastuzumab deruxtecan-associated pulmonary adverse events (AEs) using the Japanese Adverse Drug Event Report d...
Intra-arterial Injection of OTR4132, a Novel Neuroprotector in Acute Ischemic Stroke: The MaTRISS Trial [0.03%]
急性缺血性卒中动脉内注射新型神经保护药物OTR4132的疗效：马特瑞斯试验
Xavier Barreau,René Anxionnat,Olivier Heck et al.
Xavier Barreau et al.
Background and objectives: There is an important need for the development of neuroprotective therapeutic agents that could be combined to reperfusion strategies in acute ischemic stroke to improve patient prognosis. OTR41...
Aisling McGuigan
Aisling McGuigan
CT-P47/tocilizumab-anoh (AVTOZMA®) is a biosimilar of reference tocilizumab, an IL-6R inhibitor. CT-P47 is approved for treating rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idi...
A Retrospective Analysis of the Clinical and Economic Burden of Mitral Regurgitation in Italy Using Real-World Data [0.03%]
基于真实世界数据的意大利二尖瓣反流临床及经济负担回顾性分析
Paolo Sciattella,Belén Martí-Sánchez,Matteo Vernia et al.
Paolo Sciattella et al.
Introduction: Mitral regurgitation (MR) is the second most common valve disease in Europe with an increasing prevalence, causing a significant healthcare burden and impacting quality of life. Despite its clinical importan...
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Efbemalenograstim Alfa (F-627), a Novel Long-Acting rhG-CSF, in Healthy Chinese Participants: An Open-Label, Single-Center Phase I Study [0.03%]
一项在中国健康志愿者中评估Efbemalenograstim Alpha(F-627)(LY09004)，一种新型长效rhG-CSF的药代动力学，药效学，安全性和耐受性的I期开放性单中心研究
Zhihai Cao,Yao Li,Denny Hou et al.
Zhihai Cao et al.
Background and objectives: In clinical practice, granulocyte colony-stimulating factor (G-CSF) is often used to lower infection risk and avoid poor outcomes from chemotherapy dose reduction or delay. Efbemalenograstim alf...
Resmetirom: The First FDA-Approved Drug for Metabolic Dysfunction-Associated Steatohepatitis (MASH) with a Perspective on Precision Medicine [0.03%]
艾美司汀片：首个获FDA批准的代谢紊乱相关非酒精性脂肪肝炎(MASH)治疗药物及其精准医疗展望
Fengshuo Zhang,Yicong Meng,Bohan Zhao et al.
Fengshuo Zhang et al.
Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive form of metabolic dysfunction-associated steatotic liver disease (MASLD) involving hepatocyte destruction, inflammation, and typically pericellular fibrosis, potential...